[Endomyocardial fibrosis in chronic eosinophilic leukemia].
Winter
L
L
Zellweger
M J
MJ
Bremerich
J
J
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D001853:Bone Marrow / Q000473:pathology; D002869:Chromosome Aberrations; D004452:Echocardiography; D004699:Endocardium / Q000473:pathology; D004719:Endomyocardial Fibrosis / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology / Q000235:genetics; D000068877:Imatinib Mesylate; D008297:Male; D009206:Myocardium / Q000473:pathology; D015514:Oncogene Proteins, Fusion / Q000235:genetics; D010879:Piperazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D020796:Receptor, Platelet-Derived Growth Factor alpha / Q000235:genetics; D039221:mRNA Cleavage and Polyadenylation Factors / Q000235:genetics
D000970:Antineoplastic Agents; D001549:Benzamides; D015514:Oncogene Proteins, Fusion; D010879:Piperazines; D011743:Pyrimidines; D039221:mRNA Cleavage and Polyadenylation Factors; D000068877:Imatinib Mesylate; C479819:FIP1L1-PDGFRA fusion protein, human; D020796:Receptor, Platelet-Derived Growth Factor alpha